Search Patents
  • 4,4-Biarylpiperidine derivatives
    Publication number: 20040138220
    Abstract: The present invention relates to compounds of the formula I, 1
    Type: Application
    Filed: December 23, 2003
    Publication date: July 15, 2004
    Applicants: Pfizer, Inc., Pfizer Products, Inc.
    Inventor: Spiros Liras
  • 4,4-biarylpiperidine derivatives
    Patent number: 6720336
    Abstract: The present invention relates to compounds of the formula I, wherein Z1, Z2, R1, R2 and R3 are defined as in the specification, pharmaceutical compositions containing such compounds the use of such compounds to treat neurological and gastrointestinal disorders.
    Type: Grant
    Filed: July 10, 2001
    Date of Patent: April 13, 2004
    Assignees: Pfizer, Inc., Pfizer Products, Inc.
    Inventor: Spiros Liras
  • DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES
    Publication number: 20130225487
    Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).
    Type: Application
    Filed: March 12, 2013
    Publication date: August 29, 2013
    Applicant: Pfizer Inc.
    Inventor: Pfizer Inc.
  • Glucocorticoid receptor modulators
    Patent number: 6852719
    Abstract: The present invention provides non-steroidal compounds of Formula I, including prodrugs and pharmaceutically acceptable salts thereof, which are selective modulators (e.g., agonists, partial agonists and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides pharmaceutical compositions containing these compounds and methods for using these compounds to treat animals requiring glucocorticoid receptor agonist or antagonist therapy. Glucocorticoid receptor modulators are useful to treat diseases, such as obesity, diabetes, inflammation and others as described below.
    Type: Grant
    Filed: October 26, 2001
    Date of Patent: February 8, 2005
    Assignees: Pfizer Inc., Pfizer Products, Inc.
    Inventors: Kevin K. Liu, Bradley P. Morgan, Ralph P. Robinson
  • Lactams as tachkinin antagonists
    Publication number: 20040132710
    Abstract: Compounds of the formula (I): 1
    Type: Application
    Filed: December 17, 2002
    Publication date: July 8, 2004
    Applicant: Pfizer Inc.
    Inventors: Donald Stuart Middleton, Alan Stobie
  • Isothiazole derivatives useful as anticancer agents
    Publication number: 20030149048
    Abstract: The present invention relates to compounds of the formula 1 1
    Type: Application
    Filed: February 3, 2003
    Publication date: August 7, 2003
    Applicant: Pfizer Inc.
    Inventors: Eric R. Larson, Mark C. Noe, Thomas G. Gant
  • Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
    Publication number: 20040157824
    Abstract: This invention provides a compound of the formula: 1
    Type: Application
    Filed: February 3, 2004
    Publication date: August 12, 2004
    Applicant: Pfizer Inc.
    Inventors: Kazuo Ando, Tomoki Kato, Akiyoshi Kawai, Tomomi Nonomura
  • Pyrazole derivatives
    Publication number: 20040209862
    Abstract: This invention relates to the use of pyrazole derivatives of the formula 1
    Type: Application
    Filed: April 26, 2004
    Publication date: October 21, 2004
    Applicant: PFIZER, INC.
    Inventors: Romuald Gaston Corbau, Charles Eric Mowbray, Manoussos Perros, Paul Anthony Stupple, Anthony Wood
  • Thiazole derivatives
    Publication number: 20030078252
    Abstract: The invention provides compounds of formula 1 1
    Type: Application
    Filed: May 13, 2002
    Publication date: April 24, 2003
    Applicant: Pfizer Inc.
    Inventors: Mark A. Sanner, Chris J. Helal, Christopher B. Cooper
  • 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines
    Publication number: 20030162765
    Abstract: This present invention relates to compounds of the formula 1
    Type: Application
    Filed: February 20, 2003
    Publication date: August 28, 2003
    Applicant: Pfizer Inc.
    Inventors: Robert A. Volkmann, John A. Lowe, Jolanta Nowakowski
  • Isothiazole derivatives useful as anticancer agents
    Publication number: 20040152691
    Abstract: The invention relates to compounds of the formula 1 1
    Type: Application
    Filed: July 24, 2003
    Publication date: August 5, 2004
    Applicant: Pfizer Inc
    Inventors: Blaise Lippa, Tricia Ann Kwan, Joel Morris, Susan D. LaGreca, Matthew David Wessel
  • Triazole compounds useful in therapy
    Publication number: 20040162278
    Abstract: The invention provides compounds of formula (I), 1
    Type: Application
    Filed: October 24, 2003
    Publication date: August 19, 2004
    Applicant: Pfizer Inc
    Inventors: Robert Duncan Armour, Andrew Douglas Baxter, Justin Stephen Bryans, Kevin Neil Dack, Patrick Stephen Johnson, Russell Andrew Lewthwaite, Julie Newman, David James Rawson, Thomas Ryckmans
  • 4-(1,2-benzisoxazolyl)piperidine antipsychotic agents
    Patent number: 5385916
    Abstract: Certain 1-substituted 4-(1,2-benzisoxazolyl)-piperidine compounds exhibit neuroleptic activity and are useful in the treatment of psychosis and anxiety.
    Type: Grant
    Filed: October 1, 1993
    Date of Patent: January 31, 1995
    Assignee: Pfizer Inc.
    Inventor: Harry R. Howard, Jr.
  • 4-(1,2-benzisoxazolyl)piperidine antipsychotic agents
    Patent number: 5276040
    Abstract: Certain 1-substituted 4-(1,2-benzisoxazolyl)-piperidine compounds exhibit neuroleptic activity and are useful in the treatment of psychosis and anxiety.
    Type: Grant
    Filed: June 22, 1992
    Date of Patent: January 4, 1994
    Assignee: Pfizer Inc.
    Inventor: Harry R. Howard, Jr.
  • N-Benzyl-imidazoles as selective inhibitors of the thromboxane synthetase enzyme
    Patent number: 4555516
    Abstract: The N-(substituted benzyl) imidazoles are selective enzyme inhibitors and thus are useful in the treatment of heart disease, circulatory and vascular problems.
    Type: Grant
    Filed: January 9, 1980
    Date of Patent: November 26, 1985
    Assignee: Pfizer Inc.
    Inventors: Peter E. Cross, Roger P. Dickinson
  • 3-Benzylamino-2-phenyl-piperidine derivatives as substance P receptor antagonists
    Patent number: 5688804
    Abstract: The present invention relates to the derivatives of the compound of formula (I), which are useful in the treatment of inflammatory and central nervous system disorders, as well as other diorders ##STR1##
    Type: Grant
    Filed: January 31, 1995
    Date of Patent: November 18, 1997
    Assignee: Pfizer Inc.
    Inventor: Terry J. Rosen
  • Prodrug esters of phenolic 2-piperidino-1-alkanols
    Patent number: 5654302
    Abstract: Phenolic prodrug esters of certain 1-(hydroxyphenyl)-2-piperidino-1-alkanol derivatives, which are useful in the treatment of stroke, traumatic head injury and CNS degenerative disease; and intermediates useful in their synthesis.
    Type: Grant
    Filed: April 7, 1995
    Date of Patent: August 5, 1997
    Assignee: Pfizer Inc.
    Inventor: Bertrand Leo Chenard
  • ETHER BENZYLIDENE PIPERIDINE 5-MEMBERED ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS
    Publication number: 20110053982
    Abstract: The present invention relates to compounds of the Formula (I), and pharmaceutically acceptable salts thereof, and their use in the treatment of FAAH-mediated diseases or condition.
    Type: Application
    Filed: April 9, 2009
    Publication date: March 3, 2011
    Applicant: PFIZER INC.
    Inventors: Lorraine Kathleen Fay, Douglas Scott Johnson, Marvin Jay Meyers, Barbara Ann Schweitzer, Atli Thorarensen, Lijuan Jane Wang
  • NK-1 receptor antagonists for the treatment of cancer
    Patent number: 6194436
    Abstract: The present invention relates to the use of certain NK-1 receptor antagonists, as, for example, substance P receptor antagonists, to treat cancer patients, particularly cancer patients afflicted with a small cell lung carcinoma, neuroendocrine tumor or extrapulmonary small cell carcinoma.
    Type: Grant
    Filed: June 16, 1999
    Date of Patent: February 27, 2001
    Assignee: Pfizer Inc.
    Inventor: Harry Ralph Howard
  • Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
    Patent number: 6555569
    Abstract: A pharmaceutical composition containing a glycogen phosphorylase inhibitor of Formula I or IA as defined herein is administered to a mammal to treat infection.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: April 29, 2003
    Assignee: Pfizer Inc.
    Inventors: Joyce A. Sutcliffe, Judith Lee Treadway